Richter, Forest Report Positive Phase III Cariprazine Result

Gedeon Richter Nyrt., Hungary’s biggest drugmaker, and Forest Laboratories Inc. (FRX) reported today “positive” results from a Phase III clinical trial of cariprazine, an antipsychotic agent.

Data showed that patients with acute manic episodes who were treated with cariprazine “experienced significant symptom improvement compared with placebo-treated patients,” the two companies said in a statement posted on the website of the Budapest Stock Exchange today.

To contact the reporter on this story: Andras Gergely in Budapest at

To contact the editor responsible for this story: Gavin Serkin at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.